Natera registers up to 68,023 shares for resale

Accepted by SEC EDGAR 11/10/2026 - 07:55 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Natera, Inc.’s prospectus registers for resale up to 68,023 shares of its common stock by unnamed, non-affiliated selling stockholders. Of these, 45,533 closing shares were issued to the sellers on or about November 10, 2026, and an estimated 22,490 additional shares may become issuable after closing under the merger agreement.

The additional shares include holdbacks, adjustment shares, milestone shares and indemnification shares; the estimate is not a contractual cap or prediction. Natera will not receive proceeds from the resales; net sale proceeds go to the selling stockholders. Natera bears registration expenses, excluding underwriting discounts and selling commissions.

Filing Explained

The resale registration itself does not issue shares: 45,533 merger shares were already issued and are less than 1% of outstanding stock, while an estimated 22,490 additional shares remain contingent; if those are issued, they increase the share count and dilute existing holders’ ownership percentages.

Key Figures

Registered resale shares: 68,023 shares Closing shares issued: 45,533 shares Estimated potentially issuable shares: 22,490 shares +4 more

7 metrics

Registered resale shares 68,023 shares Aggregate maximum of Natera common shares offered for resale by selling stockholders.

Closing shares issued 45,533 shares Issued to the selling stockholders on or about November 10, 2026.

Estimated potentially issuable shares 22,490 shares May become issuable to selling stockholders after closing under the merger agreement.

Estimated Adjustment Shares 4,462 shares Component of the estimated potentially issuable shares.

Estimated Milestone Shares 8,770 shares Component of the estimated potentially issuable shares, contingent on specified milestones.

Common shares outstanding 145,004,521 shares As of October 31, 2026.

Closing Consideration Share Price $400.4129 per share Used as an estimate for future issuances in calculating the estimated potentially issuable shares.

Key Terms

Potentially Issuable Shares, Adjustment Holdback Shares, Fully Diluted Percentages, Non-Accredited Holders

4 terms

Potentially Issuable Shares financial

"22,490 additional shares ... that may become issuable"

Adjustment Holdback Shares financial

"Adjustment Holdback Shares and Indemnification Holdback Shares"

Fully Diluted Percentages financial

"based on their Fully Diluted Percentages"

Non-Accredited Holders regulatory

"holders who are not accredited investors"

Offering Details

secondary · 68,023 shares

Offering

Offering Type secondary

Securities Offered Common stock

Offering Amount 68,023 shares

Use of Proceeds Natera will not receive proceeds from sales by the selling stockholders; the selling stockholders receive the net sale proceeds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NTRA shares are registered for resale?

Up to an aggregate of 68,023 shares of Natera common stock are registered for resale by unnamed, non-affiliated selling stockholders. Registration does not mean the shares will be offered or sold; the sellers may offer all, some or none of them.

Will Natera receive proceeds from the NTRA resale shares?

Natera will not receive proceeds from sales of the resale shares; the selling stockholders receive the net sale proceeds, less any discounts or commissions. Natera bears expenses incident to registering the shares, excluding underwriting discounts and selling commissions.

What conditions affect NTRA's estimated additional resale shares?

The estimated 22,490 additional shares may become issuable after closing, with the actual number depending on the final post-closing purchase-price adjustment, any reduction of holdback shares for claims, achievement of the specified milestones, and whether indemnification obligations are satisfied in shares rather than cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Table of Contents

As filed with the Securities and Exchange Commission on November 12, 2026

Registration No. 333-     ​

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-3

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

NATERA, INC.

(Exact name of registrant as specified in its charter)

​	Delaware	​	​	01-0894487	​
​	(State or other jurisdiction of incorporation or organization)	​	​	(I.R.S. Employer Identification Number)	​

13011 McCallen Pass
Building A Suite 100
Austin, Texas 78753
(650) 980-9190

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Michael Brophy
Chief Financial Officer
Natera, Inc.
13011 McCallen Pass
Building A Suite 100
Austin, Texas 78753
(650) 980-9190

(Name, address, including zip code, and telephone number, including area code of agent for service)

Copies to:

​	Branden C. Berns	​	​	Daniel Rabinowitz, Esq.	​
​	Gibson, Dunn & Crutcher LLP	​	​	Secretary and Chief Legal Officer	​
​	One Embarcadero Center, Suite 2600	​	​	Natera, Inc.	​
​	San Francisco, CA 94111	​	​	13011 McCallen Pass	​
​	(415) 393-8200	​	​	Building A Suite 100	​
​	​	​	​	Austin, Texas 78753	​
​	​	​	​	(650) 980-9190	​

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​	Large accelerated filer	​	​	☒	​	​	Accelerated filer	​	​	☐	​
​	Non-accelerated filer	​	​	☐	​	​	Smaller reporting company	​	​	☐	​
​	​	​	​	​	​	​	Emerging growth company	​	​	☐	​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

​

​

Table of Contents

PROSPECTUS

NATERA, INC.

68,023 Shares

COMMON STOCK

Offered by the Selling Stockholders

​

This prospectus relates to the potential resale from time to time of up to an aggregate of 68,023 shares (“Resale Shares”) of common stock, par value $0.0001 per share, of Natera, Inc. (the “Company”) by certain unnamed, non-affiliated selling stockholders described in this prospectus (the “Selling Stockholders”). The Resale Shares consist of (i) 45,533 shares (the “Closing Shares”) of the Company’s common stock issued to the Selling Stockholders on or about November 10, 2026, in connection with the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of November 2, 2026 (the “Merger Agreement”), by and among the Company, two wholly owned merger subsidiaries of the Company, a privately held company (the “Acquired Company”) and a stockholder representative, and (ii) an estimated 22,490 additional shares that may become issuable to the Selling Stockholders after the closing pursuant to the Merger Agreement (the “Potentially Issuable Shares”), consisting of (a) Adjustment Holdback Shares and Indemnification Holdback Shares retained by the Company that may be released to the Selling Stockholders pursuant to the terms of the Merger Agreement (collectively, the “Holdback Shares”), (b) an estimated 4,462 shares that may become issuable to the Selling Stockholders in connection with a positive post-closing purchase price adjustment pursuant to the terms of the Merger Agreement (the “Adjustment Shares”), (c) an estimated 8,770 shares that may become issuable to the Selling Stockholders as milestone payments pursuant to the terms of the Merger Agreement, contingent upon the achievement of milestones specified therein (the “Milestone Shares”), and (d) shares that may become issuable to the Selling Stockholders in satisfaction of certain indemnification obligations of the Company under the Merger Agreement (the “Indemnification Shares”). Shares attributable to participants under the Change of Control Bonus Plan in connection with the positive post-closing purchase price adjustment are excluded from the Resale Shares and are being registered separately on Form S-8.

We are not offering or selling any of the Resale Shares and we will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders pursuant to this prospectus. Our registration of the securities covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the Resale Shares. The Selling Stockholders may sell the Resale Shares covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Stockholders may sell the Resale Shares in the section entitled “Plan of Distribution.”

If any underwriters, dealers or agents are involved in the sale of any of the Resale Shares, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in an applicable prospectus supplement. See the section of this prospectus entitled “Plan of Distribution” for more information.

Our common stock is listed on The Nasdaq Global Select Market under the symbol “NTRA.” On November 9, 2026, the last reported closing price of our common stock as reported on The Nasdaq Global Select Market was $320.39 per share.

Investing in our common stock involves risk. See “Risk Factors” beginning on page 8 of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is November 12, 2026.

Table of Contents​

TABLE OF CONTENTS

​	​	​	Page				​
Forward-Looking Statements	​	​	​	​	1	​	​
Where You Can Find More Information	​	​	​	​	3	​	​
Incorporation by Reference	​	​	​	​	4	​	​
Prospectus Summary	​	​	​	​	5	​	​
The Offering	​	​	​	​	7	​	​
Risk Factors	​	​	​	​	8	​	​
Use of Proceeds	​	​	​	​	9	​	​
Selling Stockholders	​	​	​	​	10	​	​
Plan of Distribution	​	​	​	​	12	​	​
Dividend Policy	​	​	​	​	14	​	​
Legal Matters	​	​	​	​	15	​	​
Experts	​	​	​	​	16	​	​

This prospectus is part of an automatic registration statement on Form S-3 that we filed with the SEC using a “shelf” registration process as a “well-known seasoned issuer,” as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”). Under this registration statement, the Selling Stockholders may sell from time to time the common stock described in this prospectus in one or more offerings or otherwise as described in the section entitled “Plan of Distribution” beginning on page 12 of this prospectus.

Neither we nor the Selling Stockholders have authorized anyone to provide you with any information other than the information contained or incorporated by reference in this prospectus, any prospectus supplement or any free writing prospectus prepared by or on behalf of us in connection with this offering to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained or incorporated by reference in this prospectus or any such prospectus supplement or free writing prospectus provided in connection with this offering is accurate only as of the date thereof, regardless of the time of delivery of such document or of any sale of our common stock. Our business, financial condition and results of operations may have changed since those dates. It is important for you to read and consider all the information contained in this prospectus, including the documents incorporated by reference herein or any free writing prospectus prepared by or on behalf of us in connection with this offering, in making your investment decision.

The Selling Stockholders are not offering to sell, or seeking offers to buy, shares of our common stock in any jurisdictions where offers and sales are not permitted. The distribution of this prospectus and the offering of the Resale Shares in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Resale Shares and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

In this prospectus, unless otherwise indicated or the context otherwise requires, the terms “Natera,” “Company,” “we,” “us” and “our” refer to Natera, Inc. All references to “this prospectus” refer to this prospectus and any applicable prospectus supplement or free writing prospectus, including the documents incorporated by reference herein and therein, unless the context otherwise requires.

i

Table of Contents​

FORWARD-LOOKING STATEMENTS

This prospectus and the documents incorporated by reference herein contain forward-looking statements. Forward-looking statements include information concerning our future results of operations and financial position, strategy and plans, and our expectations for future operations. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or the negative version of these words and similar expressions.

These forward-looking statements include, but are not limited to, statements concerning the following:

•

our expectations regarding revenue, expenses and other operating results;

​

•

our expectation that, for the foreseeable future, a significant portion of our revenues will be derived from sales of Signatera, Panorama, and Horizon;

​

•

our ability to increase demand and reimbursement for our tests;

​

•

our expectation that Panorama will be adopted for the screening of microdeletions and that third-party payer reimbursement will be available for this testing, including our expectations that the results from our Single nucleotide polymorphism-based Microdeletion and Aneuploidy RegisTry, or SMART, Study may support broader use of and reimbursement for the use of Panorama for microdeletions;

​

•

our expectations of the reliability, accuracy, and performance of our tests, as well as expectations of the benefits of our tests to patients, providers, and payers;

​

•

our ability to successfully develop additional revenue opportunities and expand our product offerings to include new tests;

​

•

our efforts to successfully develop and commercialize, or enhance, our products;

​

•

our ability to comply with federal, state, and foreign regulatory requirements, programs and policies, our expectations regarding the potential impact of governmental regulations on our business and operations, and our ability to successfully operate our business in response to changes in such requirements, programs, policies and regulations;

​

•

our ability to respond to, defend, or otherwise favorably resolve litigation or other proceedings, including investigations, subpoenas, demands, disputes, requests for information, and other regulatory or administrative actions or proceedings, including associated litigation costs we may incur and our assumptions regarding any potential liabilities associated with our existing litigation matters;

​

•

the effect of improvements in our cost of goods sold;

​

•

our estimates of the total addressable markets for our current and potential product offerings;

​

•

our ability and expectations regarding obtaining, maintaining and expanding third-party payer coverage of, and reimbursement for, our tests;

​

•

the effect of changes in the way we account for our revenue;

​

•

the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights, including associated litigation costs we may incur and our assumptions regarding any potential liabilities associated with our existing litigation matters;

​

•

our ability to successfully compete in the markets we serve;

​

•

our reliance on collaborators such as medical institutions, contract laboratories, laboratory partners, and other third parties;

​

•

our ability to operate our laboratory facilities and meet expected demand, and to successfully scale our operations;

​

•

our reliance on a limited number of suppliers, including sole source suppliers, which may impact our ability to maintain a continued supply of laboratory instruments and materials and to run our tests;

​

1

Table of Contents

•

our expectations of the rate of adoption of our current or future tests by laboratories, clinics, clinicians, payers, and patients;

​

•

our ability to complete clinical studies and publish compelling clinical data in peer-reviewed medical publications regarding our current and future tests, and the effect of such data or publications on professional society or practice guidelines or coverage and reimbursement determinations from third-party payers, including our SMART and CIRCULATE-Japan studies and our ongoing and planned trials in oncology and organ health;

​

•

our reliance on our partners to market and offer our tests in the United States and in international markets;

​

•

our expectations regarding acquisitions, dispositions and other strategic transactions and our ability to successfully integrate Foresight Diagnostics, Inc. into our business operations;

​

•

our ability to control our operating expenses and fund our working capital requirements;

​

•

the factors that may impact our financial results, including our revenue recognition assumptions and estimates; and

​

•

anticipated trends and challenges in our business and the markets in which we operate.

​

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those discussed in “Risk Factors” in this prospectus and Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 27, 2026. Given these uncertainties, you should not place undue reliance on these forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should read this prospectus completely and with the understanding that our actual future results may be materially different from what we expect.

Also, forward-looking statements represent our beliefs and assumptions only as of the date of this prospectus. Any forward-looking statement made by us in this prospectus speaks only as of the date on which it is made. Except as required by law, we disclaim any obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

2

Table of Contents​

WHERE YOU CAN FIND MORE INFORMATION

This prospectus is part of an automatic registration statement on Form S-3 that we filed with the United States Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Under this shelf registration process, the Selling Stockholders may, at any time and from time to time, offer and sell the shares described in this prospectus in one or more offerings. This prospectus, and any document incorporated by reference herein, do not contain all of the information set forth in the registration statement and its exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. For further information about us and our common stock, we refer you to the registration statement and to its exhibits. Statements in this prospectus about the contents of any contract, agreement or other document are not necessarily complete and in each instance we refer you to the copy of such contract, agreement or document filed as an exhibit to the registration statement, with each such statement being qualified in all respects by reference to the document to which it refers.

We file periodic and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains periodic and current reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge on the Investor section of our website. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website address is www.natera.com. The information on our website, or the information that can be accessed through our website, however, is not, and should not be deemed to be, a part of this prospectus.

3

Table of Contents​

INCORPORATION BY REFERENCE

The SEC allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference herein is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below (except the information contained in such documents to the extent “furnished” and not “filed”) and any future filings we make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, (except the information contained in such documents to the extent “furnished” and not “filed”):

•

our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on February 27, 2026;

​

•

the information in our Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April 23, 2026, to the extent incorporated by reference herein into our Annual Report on Form 10-K for the fiscal year ended December 31, 2025;

​

•

our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, as filed with the SEC on May 8, 2026, August 7, 2026 and November 5, 2026;

​

•

our Current Reports on Form 8-K, as filed with the SEC on April 1, 2026, June 5, 2026, June 16, 2026, and July 6, 2026, and our Current Report on Form 8-K/A, as filed with the SEC on June 16, 2026; and

​

•

the description of our common stock contained in Exhibit 4.3 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on February 26, 2021, including any amendment or report filed for the purpose of updating such description.

​

We will provide without charge upon written or oral request a copy of any or all of the documents that are incorporated by reference herein into this prospectus, other than exhibits which are specifically incorporated by reference herein into such documents. Requests should be directed to our Investor Relations department at Natera, Inc., 13011 McCallen Pass, Building A, Suite 100, Austin, Texas 78753. Our telephone number is (650) 980-9190.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein into this prospectus shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained in this prospectus (or in any document incorporated by reference herein therein) or in any other subsequently filed document that is or is deemed to be incorporated by reference herein into this prospectus modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

4

Table of Contents​

PROSPECTUS SUMMARY

You should read the following summary together with the entire prospectus and the documents incorporated by reference herein, including our consolidated financial statements and related notes as well as any free writing prospectus prepared by us or on our behalf. You should carefully consider, among other things, the matters discussed in the sections entitled “Risk Factors” included in or incorporated by reference in this prospectus.

NATERA, INC.

We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome, from samples as small as a single cell, with our statistical algorithms that incorporate data available from the broader scientific community to identify genetic variations, covering a wide range of serious conditions with high accuracy and coverage. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier and more targeted interventions that help lead to longer, healthier lives.

We currently provide a comprehensive suite of products in women’s health, oncology and organ health, as well as our Constellation cloud-based platform. We generate the majority of our revenues from the sale of Panorama, our non-invasive prenatal test (“NIPT”) and Horizon, our genetic carrier screening test. In addition to Panorama, our product offerings in women’s health also include Anora, our test to help determine underlying reasons for occurrence of miscarriage, Vistara, our single-gene NIPT that screens for conditions that may affect quality of life, and Fetal Focus, our noninvasive prenatal test for inherited conditions. Our product offerings in organ health include Prospera, a transplant rejection assessment test that evaluates risk of rejection in kidney, heart and lung transplants, and Renasight, our kidney gene panel test to determine whether there may be a genetic cause of chronic kidney disease. In oncology, in addition to Horizon, we also offer Empower, our hereditary cancer screening test, which we also offer through our oncology sales channel; Signatera, our personalized circulating tumor DNA test for molecular residual disease assessment, early recurrence monitoring and evaluation of treatment response in patients previously diagnosed with cancer, which we offer for clinical use in our CLIA (as defined below) laboratory and on a research use only basis to research laboratories and pharmaceutical companies; Latitude, our blood-based molecular residual disease test for colorectal cancer that does not require a tumor tissue sample; and Altera, our comprehensive genomic profiling test to support treatment decisions and therapy selection.

We process tests in our laboratories certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, primarily in Austin, Texas and San Carlos, California; our laboratory in Boulder, Colorado performs clinical trials testing. A portion of our testing is performed by third-party laboratories. Our customers include independent laboratories, national and regional reference laboratories, medical centers and physician practices for our screening tests, and research laboratories and pharmaceutical companies. We market and sell our tests through our direct sales force and, for our women’s health tests, through our laboratory distribution partners. We bill clinics, laboratory distribution partners, patients, pharmaceutical companies and insurance payers for the tests we perform. In cases where we bill laboratory distribution partners, our partners in turn bill clinics, patients and insurers. The majority of our revenue comes from insurers with whom we have in-network contracts. Such insurers reimburse us for our tests pursuant to our in-network contracts with them, based on positive coverage determinations, which means that the insurer has determined that the test in general is medically necessary for this category of patient.

In addition to offering tests to be performed at our laboratories, either directly or through our laboratory distribution partners, we also establish licensing arrangements with laboratories under Constellation, our cloud-based distribution model, whereby our laboratory licensees run the molecular workflows themselves and then access our bioinformatics algorithms through our cloud-based software. This cloud-based distribution model results in lower revenues and gross profit per test than cases in which we process a test ourselves; however, because we do not incur the costs of processing the tests, our costs per test under this model are also lower.

The number of tests we accession when a sample is received, entered into our computer system, and routed for processing is a key business metric. It is a subset of total tests processed, which also includes tests distributed through our Constellation licensees.

5

Table of Contents

For a description of our business, financial condition, results of operations and other important information regarding us and our business, we refer you to our filings with the SEC, incorporated by reference in this prospectus. For instructions on how to find copies of these documents, see “Where You Can Find More Information.”

We were initially formed in California as Gene Security Network, LLC in November 2003. We were incorporated in Delaware in January 2007, and we changed our name to Natera, Inc. in January 2012. Our principal executive offices are located at 13011 McCallen Pass, Building A Suite 100, Austin, Texas 78753 and our telephone number is (650) 980-9190. Our website address is www.natera.com. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus.

Natera, Panorama, Horizon, Altera, Anora, Vistara, Signatera, Empower, Prospera, Renasight and other trademarks or service marks of Natera appearing in this prospectus are the property of Natera. This prospectus contains additional trade names, trademarks and service marks of ours and of other companies. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.

6

Table of Contents​

THE OFFERING

Common stock offered by the Selling Stockholders

68,023 shares of common stock.

Use of proceeds

We will not receive any proceeds from the sale of our common stock by the Selling Stockholders pursuant to this prospectus. See “Use of Proceeds” and “Selling Stockholders.”

Plan of Distribution

The Selling Stockholders may sell all or a portion of the Resale Shares owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. Registration of the Resale Shares covered by this prospectus does not mean, however, that such shares necessarily will be offered or sold. See “Plan of Distribution.”

Risk factors

Investing in our common stock involves a high degree of risk. See “Risk Factors” and other information included or incorporated into this prospectus for a discussion of the factors you should carefully consider before deciding to invest in our securities.

The Nasdaq Global Select Market Symbol

NTRA

The Selling Stockholders may offer and sell from time to time the Resale Shares. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the Selling Stockholders, we are referring to the Resale Shares. When we refer to the selling stockholders in this prospectus, we are referring to the individuals or entities described in this prospectus as the Selling Stockholders and, as applicable, any donees, pledgees, transferees or other successors-in-interest selling shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer.

7

Table of Contents​

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described in the section entitled “Risk Factors” contained in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with all of the other information contained in this prospectus or any document incorporated by reference herein and any free writing prospectus that we may authorize for use in connection with this offering. The risks described in this prospectus or any document incorporated by reference herein are not the only risks facing us. Additional risks and uncertainties not currently known or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. If any of the unfavorable events or circumstances described in the risk factors actually occurs, our business may suffer, the trading price of our common stock and other securities could decline, and you could lose all or part of your investment.

8

Table of Contents​

USE OF PROCEEDS

We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. We will bear all fees and expenses incident to our obligation to register such Resale Shares.

9

Table of Contents​

SELLING STOCKHOLDERS

This prospectus relates to the potential resale from time to time of up to an aggregate of 68,023 shares (“Resale Shares”) of our common stock by certain unnamed, non-affiliated selling stockholders (the “Selling Stockholders”).

The Resale Shares consist of (i) 45,533 Closing Shares of the Company’s common stock issued to the Selling Stockholders on or about November 10, 2026, in connection with the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of November 2, 2026 (the “Merger Agreement”), by and among the Company, two wholly owned merger subsidiaries of the Company, the Acquired Company and a stockholder representative, and (ii) an estimated 22,490 additional shares of the Company’s common stock that may become issuable to the Selling Stockholders after the closing pursuant to the Merger Agreement (the “Potentially Issuable Shares”), consisting of the Holdback Shares, the Adjustment Shares, the Milestone Shares and the Indemnification Shares. The number of Potentially Issuable Shares is based on a good faith estimate of the number of shares issuable to the Selling Stockholders pursuant to the Merger Agreement within the next three years, calculated using the Closing Consideration Share Price of $400.4129 per share as an estimate for future issuances and assuming no reduction of the Holdback Shares for claims, the maximum positive purchase price adjustment, payment in full of both Milestone Payments and the maximum aggregate amount of indemnifiable Losses subject to the general indemnification cap. Of the Potentially Issuable Shares, 4,462 are estimated Adjustment Shares and 8,770 are estimated Milestone Shares, consisting of 5,088 shares with respect to the Integration Milestone and 3,682 shares with respect to the Revenue Milestone. The estimated Adjustment Shares reflect an allocation of the adjustment-related share estimate between the Selling Stockholders and participants under the Change of Control Bonus Plan using the Level Two Bonus Percentages applicable under the filing assumptions, with shares allocable to such participants excluded from the Potentially Issuable Shares and registered separately on Form S-8. The estimated Milestone Shares were calculated by allocating the applicable estimated net milestone payment among the Selling Stockholders based on their Fully Diluted Percentages, dividing each Selling Stockholder’s estimated dollar entitlement by $400.4129 and rounding each resulting fractional share entitlement up to the next whole share, while excluding holders who are not accredited investors or who did not provide the required accredited-investor representation (“Non-Accredited Holders”) that would receive cash in lieu of shares. Such amount is not a contractual cap or an indication or prediction of how many of such shares will ultimately be issued, because the actual number of shares issuable depends on a variety of factors, including the final post-closing purchase price adjustment, whether and to what extent the Holdback Shares are reduced in satisfaction of claims, the future trading price of the Company’s common stock, whether the milestones specified in the Merger Agreement are achieved, the cash-in-lieu treatment applicable to particular holders and whether any indemnification obligations of the Company are satisfied in shares rather than cash, among other things.

Certain Information Concerning the Selling Stockholders

The table below presents information regarding the Selling Stockholders and the shares of our common stock that they may sell or otherwise dispose of from time to time under this prospectus. As contemplated by Section 240.01 of the Regulation S-K Compliance and Disclosure Interpretations of the Commission’s Division of Corporation Finance, we are identifying the Selling Stockholders on a group basis because they beneficially hold less than 1% of our outstanding common stock prior to the offering. Certain Selling Stockholders are former officers, directors or employees of the Acquired Company and may be employees of or otherwise provide services to one or more of our subsidiaries following the acquisition. Except for such relationships and the transactions contemplated by the Merger Agreement, none of the Selling Stockholders has held a position or office or had a material relationship with us within the past three years.

For the Selling Stockholders collectively reflected in the table below, we have calculated the estimated number of Resale Shares that could become saleable by such Selling Stockholders pursuant to this prospectus if such Selling Stockholders were to receive the estimated number of Potentially Issuable Shares contemplated in this prospectus. On an aggregate basis, the total number of Resale Shares saleable pursuant to this prospectus is 68,023 shares.

For purposes of calculating the number of Resale Shares saleable pursuant to this prospectus, we have assumed that all of the Resale Shares issued or issuable to the Selling Stockholders covered by this prospectus

10

Table of Contents

are sold. However, because the Selling Stockholders can offer all, some, or none of their Resale Shares, no definitive estimate can be given as to the number of Resale Shares that the Selling Stockholders will ultimately offer or sell under this prospectus or the number of Resale Shares that will be held by the Selling Stockholders upon termination of this offering.

​

​

​

Beneficial Ownership Prior to the Date of this Prospectus

​

​

Beneficial Ownership Assuming the Sale of All Shares registered pursuant to this Prospectus

​

Name

​

​

Number of Shares(1)

​

​

Percent of Outstanding Common Stock

​

​

Number of Shares

​

​

Percent of Outstanding Common Stock

​

Selling Stockholders

​

​

​

​

45,533

​

​

​

​

​

*

​

​

​

​

​

—

​

​

​

​

​

*

​

​

​

*

Represents beneficial ownership of less than 1% of our outstanding common stock.

​

(1)

An aggregate of 45,533 shares beneficially owned by the Selling Stockholders as a group represents less than 1% of our outstanding shares of common stock prior to the offering, based on 145,004,521 shares of our common stock outstanding as of October 31, 2026. The remaining 22,490 shares may be issued to the Selling Stockholders in the future, as further described herein, but are not beneficially owned by the Selling Stockholders at this time.

​

11

Table of Contents​

PLAN OF DISTRIBUTION

The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling the Resale Shares:

•

one or more underwritten offerings;

​

•

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

​

•

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

​

•

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

​

•

an exchange distribution in accordance with the rules of the applicable exchange;

​

•

privately negotiated transactions;

​

•

“at the market” or through market makers or into an existing market for the shares;

​

•

settlement of short sales;

​

•

in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;

​

•

through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

​

•

a combination of any such methods of sale; or

​

•

any other method permitted pursuant to applicable law.

​

The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144 under the Securities Act, as amended, or the Securities Act, as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions.

Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling the Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.01.

The Selling Stockholders may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees or pledgees will be the selling beneficial owners for purposes of this prospectus.

Any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be “underwriters” within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the Resale Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

12

Table of Contents

Each Selling Stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon the Company being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer for the Resale Shares through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which the Resale Shares were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction.

Under the securities laws of some U.S. states, shares of our common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states shares of our common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

The aggregate proceeds to the selling stockholders from the sale of any Resale Shares offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus forms a part.

Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares.

We will bear all fees and expenses incident to our obligation to register the Resale Shares, excluding any underwriting discounts and selling commissions.

13

Table of Contents​

DIVIDEND POLICY

No cash dividends have ever been paid or declared on our common stock. We currently intend to retain all future earnings, if any, for use in our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors our board of directors may deem relevant.

14

Table of Contents​

LEGAL MATTERS

The validity of the issuance of the securities offered by this prospectus will be passed upon for us by Gibson, Dunn & Crutcher LLP, San Francisco, California. Certain legal matters in connection with the offered securities will be passed on for any agents, dealers or underwriters by their counsel named in the applicable prospectus supplement.

15

Table of Contents​

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, and the effectiveness of our internal control over financial reporting as of December 31, 2025, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s reports, given on their authority as experts in accounting and auditing.

16

Table of Contents

​

​

68,023 Shares

COMMON STOCK

Offered by the Selling Stockholders

​

PROSPECTUS

The date of this prospectus is November 12, 2026

​

​

Table of Contents

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14.   Other Expenses of Issuance and Distributions.

The following table sets forth the expenses to be borne by Natera, Inc. in connection with the offerings described in this Registration Statement.

​	Registration fee – Securities and Exchange Commission	​	​	​	$	1,868.70	​	​
​	Printing and engraving expenses	​	​	​	​	​ *	​	​
​	Legal fees and expenses	​	​	​	​	​ *	​	​
​	Accounting fees and expenses	​	​	​	​	​ *	​	​
​	Transfer agent fees and expenses	​	​	​	​	​ *	​	​
​	Miscellaneous	​	​	​	​	​ *	​	​
​	Total	​	​	​	​	​ *	​	​

​

*

These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time.

​

ITEM 15.   Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The amended and restated certificate of incorporation provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability:

•

for any breach of the director’s duty of loyalty to us or our stockholders;

​

•

for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

​

•

in respect of unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

​

•

for any transaction from which the director derives any improper personal benefit.

​

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

Our amended and restated certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law.

II-1

Table of Contents

Our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities reasonably incurred in connection with their service for or on our behalf. Our amended and restated bylaws provide that we shall advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding, and permit us to secure insurance on behalf of any director, officer, employee, or other enterprise agent for any liability arising out of his action in that capacity, whether or not Delaware law would otherwise permit indemnification.

We have entered into indemnification agreements with each of our directors and executive officers and certain other key employees. The indemnification agreements provide that we will indemnify each of our directors, executive officers and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his status as one of our directors, executive officers or other key employees, to the fullest extent permitted by Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding.

We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such.

ITEM 16.   Exhibits.

​

​

​

​

​

​

Incorporated by reference herein

​

​

Filed Herewith

​

Exhibit No.

​

​

Description

​

​

Form

​

​

File No.

​

​

Exhibit

​

​

Filing Date

​

3.1

​

​

Amended and Restated Certificate of Incorporation of the Registrant

​

​

8-K

​

​

001-37478

​

​

3.1

​

​

07/09/2015

​

​

​

​

3.2

​

​

Amended and Restated Bylaws of Registrant, effective as of November 3, 2021

​

​

10-Q

​

​

001-37478

​

​

3.1

​

​

11/05/2021

​

​

​

​

4.1

​

​

Form of Common Stock Certificate

​

​

S-1/A

​

​

333-204622

​

​

4.1

​

​

06/22/2015

​

​

​

​

5.1

​

​

Opinion and Consent of Gibson, Dunn & Crutcher LLP

​

​

​

​

​

​

​

​

​

​

​

​

​

​

X

​

23.1

​

​

Consent of Independent Registered Public Accounting Firm

​

​

​

​

​

​

​

​

​

​

​

​

​

​

X

​

23.2

​

​

Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

X

​

24.1

​

​

Power of Attorney (contained in the signature page hereto)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

X

​

107

​

​

Filing Fee Table

​

​

​

​

​

​

​

​

​

​

​

​

​

​

X

​

ITEM 17.   Undertakings.

(a)

The undersigned registrant hereby undertakes:

​

(1)   To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)   To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii)   To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus

II-2

Table of Contents

filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Filing Fee Table” table in the effective registration statement; and

(iii)   To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference herein in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2)   That, for the purpose of determining any liability under the Securities Act of 1933, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)   To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4)   That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(i)   If the registrant is relying on Rule 430B,

(A)   Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(B)   Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference herein into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;

(5)   That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference herein in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(6)   Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in

II-3

Table of Contents

the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

II-4

Table of Contents​

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, Natera, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on November 10, 2026.

Natera, Inc.

By:

/s/ Michael Brophy

​

​

Michael Brophy
Chief Financial Officer

Power of Attorney

Each person whose signature appears below hereby severally constitutes and appoints Solomon Moshkevich and Michael Brophy, and each of them singly, with the power to act without the other, as attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-3, and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462 promulgated under the Securities Act of 1933, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-3 has been signed below by the following persons in the capacities and on the dates indicated.

​	Signature	​	​	Title	​	​	Date	​
​	/s/ Solomon Moshkevich ​ Solomon Moshkevich	​	​	Chief Executive Officer, President and Director (Principal Executive Officer)	​	​	November 10, 2026	​
​	/s/ Michael Brophy ​ Michael Brophy	​	​	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	​	​	November 10, 2026	​
​	/s/ Matthew Rabinowitz ​ Matthew Rabinowitz	​	​	Executive Chairman of the Board of Directors	​	​	November 10, 2026	​
​	/s/ Roy Baynes ​ Roy Baynes	​	​	Director	​	​	November 10, 2026	​
​	/s/ Roelof F. Botha ​ Roelof F. Botha	​	​	Director	​	​	November 10, 2026	​
​	/s/ Rowan E. Chapman ​ Rowan E. Chapman	​	​	Director	​	​	November 10, 2026	​
​	/s/ Thomas Lynch ​ Thomas Lynch	​	​	Director	​	​	November 10, 2026	​

II-5

Table of Contents

​	Signature	​	​	Title	​	​	Date	​
​	/s/ Gail Marcus ​ Gail Marcus	​	​	Director	​	​	November 10, 2026	​
​	/s/ Herm Rosenman ​ Herm Rosenman	​	​	Director	​	​	November 10, 2026	​
​	/s/ Eric H. Rubin ​ Eric H. Rubin	​	​	Director	​	​	November 10, 2026	​
​	/s/ Jonathan Sheena ​ Jonathan Sheena	​	​	Director	​	​	November 10, 2026	​

II-6